GlassScriptPhysician profile
Kalan Nicole Bobbitt
NPI 1699923078
$4,471.16
in general payments reported to CMS, 2019-2025
36 companies · $71.89 in 2025
The $71.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $1,027 · 2021: $1,777 · 2022: $223 · 2024: $102 · 2025: $71.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,602.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $707.44 | 2019-2021 | |
| Novo Nordisk INC | $356.27 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $260.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $179.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.21 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $103.31 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $96.84 | 2019-2021 | |
| Lilly USA, LLC | $81.90 | 2019-2021 | |
| Amgen INC. | $81.49 | 2019-2020 | |
| Genentech USA, INC. | $78.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.15 | 2021-2022 | |
| Allergan, INC. | $63.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.41 | 2019-2025 | |
| Eisai INC. | $59.91 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.23 | 2019-2021 | |
| Astellas Pharma US INC | $44.47 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.05 | 2021-2022 | |
| Sanofi Pasteur INC. | $32.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $32.16 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $31.91 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.36 | 2022 | |
| Grt US Holding, INC. | $25.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.77 | 2019-2020 | |
| Tonix Medicines, INC. | $21.68 | 2025 | Tonmya |
| Dexcom, INC. | $18.36 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $18.27 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.84 | 2021 | |
| Abbott Laboratories | $17.68 | 2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $16.02 | 2025 | Contrave |
| Ironshore Pharmaceuticals INC. | $15.30 | 2019 | |
| Ibsa Pharma INC. | $14.55 | 2021 | |
| Esperion Therapeutics, INC. | $14.07 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $13.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2021 | |
| Althera Pharmaceuticals LLC | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalan Bobbitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.